262
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients

, , , , , , ORCID Icon, & show all
Pages 883-890 | Received 14 Aug 2020, Accepted 19 Nov 2020, Published online: 04 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Paola Storti, Valentina Marchica, Rosanna Vescovini, Valentina Franceschi, Luca Russo, Laura Notarfranchi, Vincenzo Raimondi, Denise Toscani, Jessica Burroughs Garcia, Federica Costa, Benedetta Dalla Palma, Nicolas Thomas Iannozzi, Gabriella Sammarelli, Gaetano Donofrio & Nicola Giuliani. (2022) Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. OncoImmunology 11:1.
Read now

Articles from other publishers (3)

Shunsuke Soma. (2022) Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins. Cureus.
Crossref
Rafael Ríos-Tamayo, Noemí Puig, Macarena Algarín, José Luís García de Veas Silva, Nuno Barbosa, Cristina Encinas, José Ángel Hernández, Rafael Alonso, María Luisa Campos, Teresa Rodríguez, Alberto Leivas, María José Olivares, María José Sánchez, Bruno Paiva, Juan José Lahuerta & Joaquín Martínez-López. (2021) The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics 11:11, pages 2020.
Crossref
Eva-Maria Klein, Diana Tichy, Hans Salwender, Elias Mai, Jan Duerig, Katja Weisel, Axel Benner, Uta Bertsch, Mabast Akhavanpoor, Britta Besemer, Markus Munder, Hans-Walter Lindemann, Dirk Hose, Anja Seckinger, Steffen Luntz, Anna Jauch, Ahmet Elmaagacli, Stephan Fuhrmann, Peter Brossart, Martin Goerner, Helga Bernhard, Marc Raab, Igor Blau, Mathias Haenel, Christof Scheid & Hartmut Goldschmidt. (2021) Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers 13:19, pages 4856.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.